Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Are CAR T-cells worth the money in lymphoma?

Anna Sureda • 20 Jun 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Are CAR T-cells worth the money in lymphoma? Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses this important question at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Anna Sureda

1:54
Looking forward to the 50th Annual Meeting of the EBMT
Anna Sureda • 7 Mar 2024
3:32
The risk of secondary malignancies following CAR T-cell therapy: current evidence
Anna Sureda • 7 Mar 2024
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:16
The success of the EBMT-EHA 6th European CAR T-cell Meeting
Anna Sureda • 7 Mar 2024

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals